Based on the correlation between the half-maximal inhibitory concentration (IC50) of drugs and ZNF503-AS2 expression, we listed the 30 most sensitive drugs and the 30 most resistant drugs for glioma patients with high ZNF503-AS2 expression (Fig 6A). Here, ZNF503 is linked to central nervous system cancer.